ABSTRACT
Introduction: Idiopathic Sudden Sensorineural Hearing Loss as a subset of sensorineural hearing loss will be confirmed by a progressive hearing loss of at least 30 dB at three contiguous frequencies over 72 hours or less. A sudden or abrupt hearing loss correlates with the time course, and a vascular event is presumptive aetiology. There is an inverse association between Omega-3 consumption and hearing loss. This study aimed to evaluate the efficacy of Omega-3 adjunctive therapy in Idiopathic Sudden Sensorineural Hearing Loss by audiometric assessments. Materials and Methods: In this randomised, triple-blind, placebo-controlled trial, all participants aged 18-70 with a history of sudden deafness (within 12 hours and ≤ 30 days) were eligible for enrollment. They were included if audiology diagnostic tests confirmed the SSNHL. Ultimately, they were randomised to the Omega-3 group and the placebo group. Results: Thirty-three patients were randomly allocated to the Omega-3 group and thirty-two to the placebo group. Vertigo (32.3% of all patients) and underlying conditions had significant relationships with complete response (C.R.)-final hearing level ≤of 25 dB in pure-tone average (P < 0.05). There was no significant difference between both groups before and after treatment. Although it was not statistically significant, patients in the Omega-3 group had faster recovery than placebo. Conclusions: Omega-3 adjunctive therapy did not have a therapeutic effect on SSNHL patients. Moreover, C.R. happened in half the patients. Vertigo and underlying conditions considerably worsen the recovery from SSNHL.
ABSTRACT
Introduction: This study was conducted to evaluate the effect of Doluperine® capsule (curcumin, piperine, and gingerol) on hearing recovery in diabetic patients with Sudden Sensorineural Hearing Loss (SSNHL). Materials and Methods: Fifty-one diabetic patients with SSNHL were randomized to receive two placebo capsules (group 1), a Doluperine® plus one placebo capsule (group 2), or two Doluperine® capsules (group 3). Moreover, all patients had an injection of dexamethasone in the middle ear. Results: The proportion of significant positive changes in PTA, SDS, and SRT was 45.4%, 45.4%, and 36.37% in group1, 84.6%, 84.6%, and 76.92% in group 2, and 70%, 50.0%, and 80.0% in group 3, respectively. Many patients in group 3 did not respond to treatment in the first month, while they recovered at the end of the second month. The chance of recovery reduced with increased time between the onset of symptoms and treatment (delayed visitation) in group 1; however, this finding was not seen in groups 2 and 3. Conclusion: Doluperine® is recommended as a complementary medicine along with steroid therapy for hearing loss improvement in diabetic patients; moreover, this herbal medicine seems to play an important role in recovery in patients with delayed visitation.
